Lyndsay J . Willmott, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Assistant Professor

Publications

• International journal of gynecological cancer
  Lokich Elizabeth, Cibula David, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gilbert Lucy, Jørgensen Trine Lembrecht, Black Destin, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Ring Kari L., Cloven Noelle, Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• Gynecologic oncology
  Powell Matthew, Grimshaw Matthew, Stevens Shadi, Coleman Robert, Mirza Mansoor, Auranen Annika, Willmott Lyndsay, Gilbert Lucy, Black Destin, Cibula David, Sharma Sudarshan, Valabrega Giorgio, Hanker Lars, Stuckey Ashley, Boere Ingrid, Landrum Lisa, Gold Michael, Shahin Mark, Pothuri Bhavana, Slomovitz Brian, Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
  190, p. S4 - S5 2024
• J Clin Oncol
  Slomovitz Brian M, Cibula David, Lv Weiguo, Ortaç Fırat, Hietanen Sakari, Backes Floor, Kikuchi Akira, Lorusso Domenica, Dańska-Bidzińska Anna, Samouëlian Vanessa, Barretina-Ginesta Maria-Pilar, Vulsteke Christof, Lai Chyong-Huey, Pothuri Bhavana, Zhang Yu, Magallanes-Maciel Manuel, Amit Amnon, Guarneri Valentina, Zagouri Flora, Bell Maria, Welz Julia, Eminowicz Gemma, Hruda Martin, Willmott Lyndsay J, Lichfield Jasmine, Wang Wei, Orlowski Robert, Aktan Gursel, Gladieff Laurence, Van Gorp Toon, Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors, p. JCO2401887 2024
• International journal of gynecological cancer
  Lorusso Domenica, Collins Dearbhaile, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• Journal of clinical oncology
  Santin Alessandro D, Willmott Lyndsay, Corr Bradley R, Spira Alexander, Butrynski James, Tse Ka Yu, Patel Jilpa, Mekan Sabeen, Wu Tia, Lin Kai-Wen, Kuo Peiwen, Dumbrava Ecaterina E, Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer, p. JCO2302767 2024
• Journal of clinical oncology
  Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah, Monk Bradley J., Cloven Noelle, Podzielinski Iwona, Nevadunsky Nicole, Ring Kari L., Myers Tashanna K. N., Dabrowski Christine, Stevens Shadi, Mirza Mansoor Raza, Willmott Lyndsay, Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial
  42:16_suppl, p. 5607 - 5607 2024
• Clinical cancer research
  Lorentzen Georgia M, Laniewski Pawel, Cui Haiyan, Mahnert Nichole D, Mourad Jamal, Borst Matthew P, Willmott Lyndsay, Chase Dana M, Roe Denise J, Herbst-Kralovetz Melissa M, Cervicovaginal metabolome and tumor characteristics for endometrial cancer detection and risk stratification 2024
• Therapeutic advances in medical oncology
  Auranen Annika, Sukhin Vladyslav, Powell Matthew A., Landrum Lisa M., Ronzino Graziana, Buscema Joseph, Bauerschlag Dirk, Lalisang Roy, Bender David, Gilbert Lucy, Armstrong Amy, Safra Tamar, Nevadunsky Nicole, Sebastianelli Alexandra, Slomovitz Brian, Ring Kari, Coleman Robert, Podzielinski Iwona, Stuckey Ashley, Teneriello Michael, Gill Sarah, Pothuri Bhavana, Willmott Lyndsay, Sharma Sudarshan, Dabrowski Christine, Antony Grace, Stevens Shadi, Mirza Mansoor Raza, Fleming Evelyn, Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
  16, p. 17588359241277656 - 2024
• Journal of minimally invasive gynecology
  Stewart Chelsea, Moreno Andrea, Vo Elise, Bhattarai Bikash, Farley John, Willmott Lyndsay, Monk Bradley, Chase Dana, Factors associated with inpatient narcotic medication usage after robotic assisted laparoscopy 2023
• Journal of geriatric oncology
  Moore Madison S., Willmott Lyndsay J., Chase Dana M., Vo Elise H., Bhattarai Bikash, Farley John H., Monk Bradley J., Robotic-assisted gynecologic surgery in an older population: A comparison study
  14:6, p. 101533 - 101533 2023
• International journal of gynecological cancer
  Oaknin Ana, Herzog Thomas J, Beiner Mario E, Copeland Larry J, McNeish Iain A, Mahdi Haider S, Lim Myong Cheol, Kristeleit Rebecca S, Salinas Erin A, de Vivo Rocco, Wilson Michelle K, Liontos Michalis, Santin Alessandro D, Provencher Diane M, Demirkiran Fuat, Willmott Lyndsay J, Chudecka-Głaz Anita M, Lin Kevin K, Monk Bradley J, 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246)
  32:Suppl 2, p. A472 - A472 2022
• International journal of gynecological cancer
  Chase D M, Backes F, Han S, Graybill W, Romeo Marin M, Lund B, Pothuri B, Mangili G, O’malley D, Berton D, Willmott L, Baumann K, Coleman R, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl F, Woodward T, Monk B J, Gonzalez-Martin A, 961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial
  31:Suppl 3, p. A284 - A284 2021
• Gynecologic oncology
  Eakin C., Zhang J., Kindall E., Bhattarai B., Willmott L., Chase D., Cervical Cancer Screening in Pregnancy: Identifying Characteristics of Poor Postpartum Follow-up
  156:3, p. e36 - e36 2020
• Gynecologic oncology
  Moreno A., Vo Elise, Bhattarai B., Patel S., Farley J., Willmott L., Monk B., Chase D., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, Monk Bradley J., Chase Dana, Shields Kristin M., Willmott Lyndsay J., Farley John, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Barnes Dominique, Willmott Lyndsay J., Farley John, Monk Bradley J., Chase Dana, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Vo E.H., Moreno A.E., Bhattarai B., Patel S., Farley J.H., Monk B.J., Willmott L.J., Chase D.M., Robotic-assisted Gynecologic Surgery in an Elderly Population: A Comparison Study
  147:1, p. 204 - 205 2017
• Journal of clinical oncology
  Love Neil, Birrer Michael J., Hecht J. Randolph, Wakelee Heather A., Chen Gigi Qiqi, Deutsch Margaret Ann, Picton Maria Eugenia, Rodriguez Estelamari, Willmott Lyndsay, Kelly Gloria, Miller Kirsten, Moss Jonathan, Paley Douglas, Ziel Kathryn, The morbidity and mortality conference (MMC) concept applied to contemporary oncology practice: Retrospective findings on management of 233 patients (pts) who died of ovarian cancer (OC), colorectal cancer (CRC), and wild-type (no identified targetable mu
  35:8_suppl, p. 241 - 241 2017
• Gynecologic oncology research and practice
  Minion Lindsey E., Chase Dana M., Farley John H., Willmott Lyndsay J., Monk Bradley J., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Journal of gynecologic surgery
  Shields Kristin M., Willmott Lyndsay J., Sumner Daniele A., Minion Lindsey E., Monk Bradley J., Ten-Year Food and Drug Administration Reporting on Robotic Complications in Gynecologic Surgery
  31:6, p. 331 - 335 2015
• Gynecologic oncology
  Shields K.M., Willmott L., Farley J.H., Monk B.J., Chase D., Factors associated with low educational background in uterine cancer patients
  137, p. 123 - 123 2015
• Gynecologic oncology
  Craig C., Gibson S.J., Osann K.E., Farley J., Willmott L., Monk B.J., Chase D.M., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Angiogenesis (London)
  Trapp Valerie, Parmakhtiar Basmina, Papazian Vartan, Willmott Lyndsay, Fruehauf John P., Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
  13:4, p. 305 - 315 2010
• Cancer research (Chicago, Ill.)
  Willmott Lyndsay J., Monk Bradley, Al-Ghazi Muthana, Fruehauf John, Abstract 1399: The effect of radiation therapy with adjunctive oxaliplatin versus cisplatin chemotherapy in cervical cancer cell lines
  70:8_Supplement, p. 1399 - 1399 2010
• Gynecologic oncology
  Monk Bradley J., Willmott Lyndsay J., Sumner Daniele A., Anti-angiogenesis agents in metastatic or recurrent cervical cancer
  116:2, p. 181 - 186 2010
• Journal of the National Comprehensive Cancer Network
  Willmott L. J., Sumner D. A., Monk Bradley J., Biologics in Cervical Cancer Therapy
  8:12, p. 1417 - 1423 2010
• Journal of oncology
  Willmott Lyndsay J., Fruehauf John P., Targeted Therapy in Ovarian Cancer
  2010, p. 740472 - 9 2010
• Expert review of anticancer therapy
  Willmott Lyndsay J, Monk Bradley J, Cervical cancer therapy: current, future and anti-angiogensis targeted treatment
  9:7, p. 895 - 903 2009